NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00004-0352-30 | 00004-0352 | Peginterferon alfa-2a | Pegasys | Immunotherapy | Cytokine | Interferon | Feb. 22, 2011 | Aug. 22, 2011 | No Longer Used | ||
00004-0352-39 | 00004-0352 | Peginterferon alfa-2a | Pegasys | Immunotherapy | Cytokine | Interferon | Oct. 16, 2002 | July 31, 2015 | No Longer Used | ||
00004-0352-98 | 00004-0352 | Peginterferon alfa-2a | Pegasys | Immunotherapy | Cytokine | Interferon | Oct. 16, 2002 | July 31, 2015 | No Longer Used | ||
71287-0219-02 | 71287-0219 | brexucabtagene autoleucel | TECARTUS | 2000000.0 1/68mL | Immunotherapy | CAR-T | CD19 | Intravenous | July 24, 2020 | In Use | |
00173-0821-01 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | July 22, 2011 | Aug. 31, 2017 | No Longer Used |
00173-0821-02 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | July 22, 2011 | Aug. 31, 2017 | No Longer Used |
00173-0821-33 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | July 22, 2011 | Aug. 31, 2017 | No Longer Used |
29336-0610-12 | 29336-0610 | Imiquimod | Aldara | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Sept. 24, 2010 | Jan. 31, 2015 | No Longer Used | |
29336-0610-24 | 29336-0610 | Imiquimod | Aldara | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | June 24, 2011 | June 24, 2011 | No Longer Used | |
00006-3026-02 | 00006-3026 | Pembrolizumab | Keytruda | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Jan. 15, 2015 | In Use |
Found 10,000 results in 3 milliseconds — Export these results